Biogen Inc. BIIB
252.49 USD -0.91 (-0.36%)
Nov 12, 2026, 1:36 PM EST
250.64 Day range 255.05
161.48 52-week range 254.87
- YTD
- +43.47%
- 1 year
- +56.36%
News
247wallst.com Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs Two neighbors get the same Alzheimer's diagnosis and the same prescription, yet only one can count on a manageable bill. A missed registry rule and a closed enrollment window could decide who pays,…
defenseworld.net Biogen Inc. $BIIB Stock: Alpha Family Trust Boosts Holdings Alpha Family Trust raised its position in Biogen Inc. (NASDAQ: BIIB) by 659.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange…
benzinga.com Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305 Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $245 to $305.
benzinga.com UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO Analyses Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP…
globenewswire.com ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure BRUSSELS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced further data characterizing the clinical profile of…
benzinga.com Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth Most national private drug plans now provide coverage for ZURZUVAE™, broadening access for eligible Canadian patients with private insurance coverage.Toronto, November 5, 2026 — Biogen Canada Inc.…
businesswire.com Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone) TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression…
benzinga.com Guggenheim Maintains Buy on Biogen, Raises Price Target to $300 Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
benzinga.com HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270 HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.
benzinga.com Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.- benzinga.com Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272 Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.
benzinga.com Argus Research Upgrades Biogen to Buy, Announces $280 Price Target Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
benzinga.com RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272 RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.
benzinga.com Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $238 Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $231 to $238.- benzinga.com TD Cowen Maintains Buy on Biogen, Raises Price Target to $260 TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $250 to $260.
- benzinga.com Wedbush Maintains Neutral on Biogen, Raises Price Target to $225 Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.
- benzinga.com Truist Securities Reiterates Buy on Biogen, Raises Price Target to $260 Truist Securities analyst Danielle Brill reiterates Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $235 to $260.
benzinga.com Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
benzinga.com These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.- benzinga.com Baird Maintains Outperform on Biogen, Raises Price Target to $290 Baird analyst Brian Skorney maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $250 to $290.
- benzinga.com Needham Maintains Buy on Biogen, Raises Price Target to $290 Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $256 to $290.
- benzinga.com Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $230 Barclays analyst Emily Field maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $200 to $230.
benzinga.com Biogen Q3 2026 Earnings Call Transcript Biogen (NASDAQ:BIIB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com CORRECTION: Biogen Narrows FY2026 Adj EPS Guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 Est Biogen (NASDAQ:BIIB) narrows FY2026 Adj EPS guidance from $15.85-$16.85 to $15.95-$16.75 vs $12.36 analyst estimate..
benzinga.com Biogen Raises FY2026 GAAP EPS Guidance from $12.00-$13.00 to $12.20-$13.00 vs $5.84 Est Biogen (NASDAQ:BIIB) lowers FY2026 Adj EPS guidance from $15.25-$16.25 to $12.20-$13.00 vs $12.36 analyst estimate..- benzinga.com B of A Securities Maintains Neutral on Biogen, Raises Price Target to $244 B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $219 to $244.
- benzinga.com TD Cowen Maintains Buy on Biogen, Raises Price Target to $250 TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $250.
- benzinga.com Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310 Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.
- benzinga.com Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the…
- benzinga.com JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300 JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
- benzinga.com RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256 RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $260 to $256.
benzinga.com 4 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated Biogen Inc. (NASDAQ:BIIB) today announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN,…
- benzinga.com HSBC Maintains Reduce on Biogen, Raises Price Target to $175 HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.
- benzinga.com Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today…
- benzinga.com Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245 Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.
- benzinga.com Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector:…
- benzinga.com Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today…
- benzinga.com RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260 RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $240 to $260.
- benzinga.com Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced today that once weekly lecanemab-irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy…
- benzinga.com Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.
- benzinga.com Mizuho Maintains Outperform on Biogen, Raises Price Target to $241 Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.
- benzinga.com Citigroup Maintains Neutral on Biogen, Raises Price Target to $215 Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $200 to $215.
- benzinga.com HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251 HC Wainwright & Co. analyst Andrew S. Fein maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231 Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.
- benzinga.com RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240 RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $242 to $240.
- benzinga.com Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248 Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $245 to $248.